Artikel

You have free access to this content

Die Fettsäuresynthese als Angriffspunkt

Von alten und neuen antimykobakteriellen Wirkstoffen

  1. Christine M. Topf,
  2. Johannes Schiebel,
  3. Prof. Dr. Caroline Kisker,
  4. Prof. Dr. Ulrike Holzgrabe

Article first published online: 2 JAN 2012

DOI: 10.1002/pauz.201100454

Issue

Pharmazie in unserer Zeit

Pharmazie in unserer Zeit

Volume 41, Issue 1, pages 64–70, Januar 2012

Additional Information

How to Cite

Topf, C. M., Schiebel, J., Kisker, C. and Holzgrabe, U. (2012), Die Fettsäuresynthese als Angriffspunkt. Pharmazie in unserer Zeit, 41: 64–70. doi: 10.1002/pauz.201100454

Author Information

  1. Institut f. Pharmazie und LMC, Universität Würzburg, Am Hubland, 97074 Würzburg

Publication History

  1. Issue published online: 2 JAN 2012
  2. Article first published online: 2 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (1307K)

REFERENCES

  • 1
    Chan, D.I., Vogel, H.J., Current understanding of fatty acid biosynthesis and the acyl carrier protein. Biochem. J. (2010) 430, 1–19.
  • 2
    Maier, T., Jenni, S., Ban, N., Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science (2006) 311, 1258–1262.
  • 3
    Machutta, C.A., Bommineni, G.R., Luckner, S.R., Kapilashrami, K., Ruzsicska, B. et al., Slow onset inhibition of bacterial β-ketoacyl-acyl carrier protein synthases by thiolactomycin. J. Biol. Chem. (2010) 285, 6161–6169.
  • 4
    Sullivan, T.J., Truglio, J.J., Boyne, M.E., Novichenok, P., Zhang, X. et al., High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. (2006) 1, 43–53.
  • 5
    Price, A.C., Choi, K.-H., Heath, R.J., Li, Z., White, S.W., Rock, C.O., Inhibition of β-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. J. Biol. Chem. (2001) 276, 6551–6559.
  • 6
    Brown, A.K., Taylor, R.C., Bhatt, A., Fütterer, K., Besra, G.S., Platensimycin activity against mycobacterial βketoacyl-ACP synthases. PLoS ONE 4, (2009) e6306.
  • 7
    Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., Poyart, C., Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature (2009) 458, 83–86.
  • 8
    Luckner, S.R., Machutta, C.A., Tonge, P.J., Kisker, C., Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin. Structure (2009) 17, 1004–1013.
  • 9
    Kamal, A., Azeeza, S., Malik, S., Shaik, A.A., Rao, M.V., Efforts towards the development of new antitubercular agents: Potential for thiolactomycin based compounds. J. Pharm. Pharmaceut. Sci. (2008) 11, 56s–80s.
  • 10
    Lu, H., Tonge, P.J., Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Accounts Chem. Res. (2007) 41, 11–20.
  • 11
    Freundlich, J.S., Wang, F., Vilcheze, C., Gulten, G., Langley, R. et al., Triclosan derivatives: Towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. Chem. Med. Chem. (2009) 4, 241–248.
  • 12
    Luckner, S.R., Liu, N., am Ende, C.W., Tonge, P.J., Kisker, C., A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis. J. Biol. Chem. (2010) 285, 14330–14337.
  • 13
    He, X., Alian, A., Ortiz de Montellano, P.R., Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorgan. Med. Chem. (2007) 15, 6649–6658.
  • 14
    Pages, L.B., Castro Pichel, J., Gonzalez Menendez, R., Fernandez Velando, E.P., Gonzalez del Valle, S., et al.: (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (Pyrazol-3-yl)-1,3,4-thiazol-2-amine Compounds. GlaxoSmithKline (2010), WO 2010/118852 A1.
Get PDF (1307K)